1. RESEARCH POSTER PRESENTATION DESIGN © 2012
www.PosterPresentations.com
• In resource limited settings, the use of
DBS for HIV-1 and Hepatitis diagnosis
has become essential for optimal
disease management.
• Several studies have evaluated the
performance of Whatman 903 device
with the RT assay.
• The objective of this study was to
compare the performance of the
HemaSpot and Whatman 903 devices
using the RT assay.
• In addition, this study evaluated the
performance of the devices with the
m2000sp automation.
Conclusion
• Third HCV World Health Organization
(WHO) International Standard (IS)
was used to generate whole blood
(ProMedDx (Norton, Ma) panels
targeting the following
concentrations: 5000IU/mL,
2500IU/mL, 1250IU/mL and
625IU/mL.
• Seventy five microliters of whole
blood was spotted on Whatman 903
and HemaSpot devices and air dried
overnight at room temperature.
• Panels were placed at 8C overnight
for long term storage.
• One full spot from each device was
incubated in 1.3mL of m2000
proprietary elution buffer for 45min.
• Samples were gently vortexed and
transferred to m2000sp for
extraction. RNA extraction was
performed using 1ml extraction
protocol and the performance of the
RT assay was assessed.
• Intra and Inter-run reproducibility
was evaluated across 3 different
runs.
• The enhanced mPLUS capability provides the clinical laboratories
with increased efficiencies to meet the increasingly stringent
turnaround time requirements without increased costs associated
with discarding partially used amplification reagents.
• This solution offers a combination of automation, flexibility,
efficiency and test menu unmatched in the field today.
Evaluation of novel sample collection device using the Abbott RealTime HCV assay (RT)
Danijela Lucic Ph.D.1, Christine Herman1, Jeanette Hill2, Shelley Hossenlopp2, Gavin Cloherty1
1Abbott Molecular , Des Plaines, IL; 2Spot On Sciences, Austin, TX
Introduction
• Whatman device demonstrated
100% detectability at 5000IU/mL
(n=12), 90% detectability at
2500IU/mL (n=30) and 1250IU/mL
(n=20) and only 70% detectability at
625IU/mL (n=29).
• HemaSpot device demonstrated
100% detectability at 5000IU/mL
(n=15), 1250IU/mL (n=30) and
625IU/mL while 97% detectability
was observed at 2500IU/mL (n=30).
• Intra-run reproducibility did not
exceed 0.30 log copies/mL at any
level (Table 1).
• Inter-run reproducibility did not
exceed 0.33 log copies/mL at any
level (Table 2).
Results Results Continued
Figure 1: HemaSpot device
Figure 2: HCV detectability at 5000, 2500, 1250 and 625 IU/mL.
Table 1a: Whatman Intra-run Reproducibility
Table 1b: HemaSpot Intra-run Reproducibility
Table 2: Inter-run Reproducibility
Methods